New drugs for the therapy of mycobacterial infections

被引：6

作者：

Bermudez, LE ^{[1
]}

Young, LS ^{[1
]}

机构：

[1] KUZELL INST ARTHRITIS & INFECT DIS,CALIF PACIFIC MED CTR,RES INST,SAN FRANCISCO,CA 94115

来源：

CURRENT OPINION IN INFECTIOUS DISEASES | 1995年 / 8卷 / 06期

关键词：

D O I：

10.1097/00001432-199512000-00005

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

The worldwide epidemic of AIDS has introduced the need for compounds with activity against mycobacteria. Furthermore, resistant strains both of Mycobacterium tuberculosis and of Mycobacterium avium have been isolated from patients with increasing frequency. This review focuses on new antimicrobials with in-vitro or in-vivo activity, or both, against mycobacteria, such as new rifamycins, quinolones, nitroimidazoles, oxazolidinones, macrolides, and tetracyclines.

引用

页码：428 / 437

页数：10